An open label randomized phase II study of pasireotide with or without everolimus in castrate-resistant chemotherapy-naïve prostate cancer patients

Published

Journal Article

© 2015 Elsevier Ltd. New areas of research continue to examine the role of non-androgen receptor pathways in prostate cancer treatment. The phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin (mTOR) pathway may be a target for prostate cancer therapy. Somatostatin receptor signaling inhibits intracellular PI3K/Akt signaling, making it an attractive target for combination therapy. We conducted a phase II open label clinical trial examining the use of somatostatin receptor agonist, pasireotide (SOM230) in combination with mTOR inhibitor, everolimus in metastatic castrate-resistant chemotherapy-naïve prostate cancer patients. Of the 6 patients enrolled in the study, only 1 patient had >50% PSA reduction from baseline. Three patients withdrew due to grade 3 adverse events. The study was closed early due to toxicity profiles and no further development was planned for this combination treatment in prostate cancer.

Full Text

Duke Authors

Cited Authors

  • Lin, J; Deng, A; Hoffman-Censits, J; Gibney, G; Hyslop, T; Miller, B; Kilpatrick, D; Jabbour, S; Kevin Kelly, W

Published Date

  • January 1, 2015

Published In

Volume / Issue

  • 4 /

Start / End Page

  • 192 - 195

International Standard Serial Number (ISSN)

  • 2213-0896

Digital Object Identifier (DOI)

  • 10.1016/j.ctrc.2015.11.003

Citation Source

  • Scopus